Newsroom

Sorted by: Latest

-

Zumigo InstaAuth Achieves FIDO2 Server Certification, Bringing Frictionless, Secure Passkey Sign-In to Banks, Fintechs, and Merchants

SAN JOSE, Calif.--(BUSINESS WIRE)--Zumigo InstaAuth earns FIDO2 Server Certification for phishing-resistant passkey sign-in, paired with carrier-grade phone verification....
-

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC). The live webcast of the conference call may...
-

NRG Energy, Inc. Announces Quarterly Dividend

HOUSTON--(BUSINESS WIRE)--NRG Energy, Inc. (NYSE: NRG) today announced that its Board of Directors declared a quarterly dividend on the Company’s common stock of $0.475 per share, or $1.90 per share on an annualized basis. The dividend is payable on November 16, 2026, to stockholders of record as of November 2, 2026. About NRG NRG is a leading provider of electricity, natural gas, and smart home solutions to eight million customers across North America. The company operates a customer-first pla...
-

Berkshire Hathaway Specialty Insurance Announces Entry Into Poland and Carsten Keune as Country Manager

BOSTON & WARSAW, Poland & COLOGNE, Germany--(BUSINESS WIRE)--Berkshire Hathaway Specialty Insurance Announces Entry Into Poland, and Carsten Keune as Country Manager...
-

Frontier Medicines to Present First Clinical Data for FMC-376, an Equipotent KRAS G12C ON+OFF Inhibitor, at ESMO Congress 2026

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced the company will present promising preliminary clinical data from the ongoing Phase 1 portion of its Phase 1/2 PROSPER trial evaluating FMC-376, an equipotent KRAS G12C ON+OFF inhibitor, in patients with advanced KRA...
-

Silgan Announces Strategic Portfolio Acceleration; Establishes Partnership to Acquire Trivium

NORWALK, Conn. & AMSTERDAM & NEW YORK--(BUSINESS WIRE)--Silgan Holdings Inc. (NYSE: SLGN) (“Silgan” or the “Company”), Trivium Packaging B.V. (“Trivium”), and funds affiliated with American Industrial Partners ("AIP") today announced a proposed transaction that will combine Silgan's Metal Containers segment and Food and Beverage Flat Cap Closures businesses with Trivium to create Silgan Metal Containers and Closures (“Silgan MCC”). The combination is a transformational next step that accelerate...
-

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be...
-

SES AI Completes Ramp of Korea Drone Battery Plant to One Million NDAA-Compliant Cells Per Year, and Plans to Further Expand to Three Million NDAA-Compliant Cells Per Year by Second Quarter 2027

WOBURN, Mass.--(BUSINESS WIRE)--SES AI Corporation (“SES AI,” the “Company,” “we” or “us”) (NYSE: SES), a global leader in the development and manufacturing of AI-enhanced high-performance Li-Metal and Li-ion batteries, today announced that it has completed the ramp up of its drone battery plant in Chungju, Korea, to an annual production capacity of one million NDAA-compliant cells. Driven by stronger than expected customer demand, the Company plans to immediately begin expanding the plant furt...
-

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, today announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named “TriGemX Bio, Inc.” (the “Combined Company”...
-

monday.com to Announce Third Quarter 2026 Financial Results on Monday, November 9, 2026

NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--monday.com (NASDAQ: MNDY) today announced it will report its financial results for the third quarter of 2026 on Monday, November 9, 2026. monday.com management will host a conference call and webcast to discuss the results that morning at 8:30 a.m. Eastern Time.Information about monday.com’s financial results, including a link to the live webcast of the conference call, will be made available on monday.com’s investor relations website at https://ir.m...